Critical Biologics Corporation Obtains $1,500,000 Series A Funding

  • Feed Type
  • Date
    8/22/2008
  • Company Name
    Critical Biologics Corporation
  • Mailing Address
    124 Mt. Auburn St. Cambridge, MA 02138
  • Company Description
    In particular, CBC is focused on a theranostic approach to treat critical care patients with low plasma gelsolin levels at high risk of life-threatening complications.
  • Website
    http://www.criticalbiologics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,500,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The funds will enable CBC to advance its lead recombinant human plasma gelsolin (rhu-pGSN) targeted for the prevention of life-eatening critical care complications associated with low plasma gelsolin levels.
  • M&A Terms
  • Venture Investor
    Morningside Group

By posting a comment, you agree to our terms and conditions.